4-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-N-(1,3-oxazol-2-ylmethyl)cyclohex-3-ene-1-carboxamide | 1416308-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-N-(1,3-oxazol-2-ylmethyl)cyclohex-3-ene-1-carboxamide
• 英文别名: 4-[1-(2,2-dimethylpropyl)-3-methyl-2-oxoimidazo[4,5-b]pyridin-5-yl]-N-(1,3-oxazol-2-ylmethyl)cyclohex-3-ene-1-carboxamide
• CAS: 1416308-81-0
• 化学式: C₂₃H₂₉N₅O₃
• 分子量: 423.515
• InChiKey: JMKYLIZUPROHTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  91.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] IMIDAZOPYRIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDIN-2-ONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012174199A1

  公开（公告）日：2012-12-20

  The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及咪唑吡啶-2-酮衍生物，这些衍生物是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病方面具有用途。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗代谢型谷氨酸受体参与的这类疾病中使用这些化合物和组合物。
• IMIDAZOPYRIDIN-2-ONE DERIVATIVES
  申请人：Fiji Hannah D.

  公开号：US20140350002A1

  公开（公告）日：2014-11-27

  The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR 2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及咪唑吡啶-2-酮衍生物，其是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的这些疾病方面的使用。
• US9315518B2
  申请人：——

  公开号：US9315518B2

  公开（公告）日：2016-04-19